Omeros seeks orphan-drug status for rare disease drug

04/22/2013 | Pharmaceutical Business Review Online

Omeros submitted an application to the FDA seeking orphan-drug designation for OMS721, an investigational drug for atypical hemolytic uremic syndrome. The drug, which targets the lectin pathway of the complement system, is formulated for self-administration through subcutaneous injection. The firm plans to apply for a similar designation in Europe and to initiate clinical studies in the summer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ